Introduction
The vitamin K antagonists (VKA, e.g. warfarin) were traditionally the only available oral anticoagulants (OAC) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF), but more recently three non-VKA oral anticoagulants (NOACs), dabigatran, rivaroxaban and apixaban have become licensed for stroke prevention in AF, with a fourth, edoxaban, on the horizon, subject to regulatory approval. 1 2 3 4 Treatment guidelines have evolved to reflect the availability of NOACs. The European Society of Cardiology (ESC) 5 and National Institute for Health and Care Excellence guidelines (NICE) 6 recommend a simple 2-step approach:
first, to initially focus on the identification of low risk patients (essentially CHA 2 DS 2 -VASc score [Congestive heart failure, Hypertension, Age ≥ 75 years {double}, Diabetes mellitus, previous thromboembolism {double}, Vascular disease, Age 65-74 years, and female gender] =0 if male, 1 if female) who do not need any antithrombotic therapy; step 2 is to offer OAC to all other AF patients with ≥1 additional stroke risk factors, whether as a NOAC or well controlled VKA.
In Japan, the Japanese Circulation Society (JCS) guidelines have focused on using the older CHADS 2 score (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and previous stroke/transient ischemic attack [double]), and do not operationalize a stepwise approach to OAC management decisions. The JCS guidelines recommend OAC in high-risk patients with a CHADS 2 score ≥2; 'prefer' the use of dabigatran or apixaban for those at intermediate-risk (CHADS 2 score=1); and for 'other risk factors' (age 65-74, cardiomyopathy, vascular disease)' OAC may be considered 7 . M A N U S C R I P T ACCEPTED MANUSCRIPT 5 The net clinical benefit (NCB) of OACs has been studied in 'real world' populations in Western countries, where a positive net clinical benefit, balancing stroke against serious bleeding, is evident for patients with a CHA 2 DS 2 -VASc score of ≥1. 8, 9 Modelling NOAC data use provides evidence of even greater NCB. 10 There are currently no data on the potential impact on stroke reduction in Japan by using a CHA 2 DS 2 -VASc score management approach (as opposed to the CHADS 2 score used within the JCS guidelines) to aid OAC-decision making.
Given the benefit of OACs even in patients with ≥ 1 stroke risk factors, we performed a modeling analysis to investigate stroke events associated with the different OACs and compared the approach to stroke risk stratification based on the 2014 JCS guidelines approach (based on the CHADS 2 score) and the ESC guidelines approach (based on CHA 2 DS 2 -VASc score), using event rates from a previously published cohort of nonanticoagulated Japanese patients with NVAF 11 . The focus of the modeling analysis is to highlight the missed opportunities for stroke prevention with OACs by using the CHADS 2 score instead of the CHA 2 DS 2 -VASc score, with reference to the 2014 JCS guideline as an illustrative example.
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Methods
Our modeling approach is summarized in Figure 1 . The 'base case' study population used for our model was 
Model assumptions
The event rates per 100 person years for IS/TE (Table 1) were calculated using data from the published paper by Komatsu et al. 11 for patients on no treatment, stratified by stroke risk as predicted by the CHADS 2 13 and CHA 2 DS 2 -VASc scores. 14 These data were compared with the studies of Siu et al. 15 , Guo et al. 16 and Lip et al. 14 In the study by Siu et al. 15 , a total of 10,195 Chinese patients with a diagnosis of AF were identified from a computer-based hospital clinical management system. Patients were excluded if they had significant valvular heart disease including previous valvular surgery, valvular disease with planned surgical correction, and any degree of mitral stenosis, or incomplete clinical and/or follow-up data.
In the study by Guo et al. 16 , patients with AF admitted to the PLA General Hospital were eligible for this study.
Inclusion criteria were a pre-existing diagnosis of permanent, persistent, or paroxysmal AF, development of newonset AF during their current admission (defined on having an ECG or Holter recording).
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In the study by Lip et al. 14 , detailed survey methods, center participation, patient characteristics, management and definitions of the baseline and follow-up survey of the Euro Heart Survey on AF have previously been described. 17 18 In summary, 5,333 ambulant and hospitalized patients with AF were enrolled from the cardiology practices of 182 hospitals in 35 European countries. Patients were enrolled if they were ≥ 18 years old and if they had an ECG or Holter recording showing AF during the qualifying admission/consultation or in the preceding 12 months.
By using data from Komatsu et al. 11 , the estimated event rates and the number of IS/TE events were estimated for a hypothetical Japanese AF population of n=100,000 ( Table 2 ). Using data from recent trials of the NOACs, the potentially preventable stroke events were calculated in this population ( The relative risks of IS/TE were assumed to be constant across all categories of stroke risk. On the basis of the general prevalence of AF in the Japanese (0.56%) in 2003 19 , we estimated that a population prevalence of AF in Japan for 2014 to be 0.7% (n=889,000), given that the prevalence of AF in Japan might be increased in its ageing society. The total population of Japan was assumed about 127,000,000 based on the recent world population review. 20 In the paper of Komatsu et al. 9 , the overall observed stroke rate was 2.1%/year. Using these estimated figures, we modeled the potential stroke events in the total AF population for the whole of Japan, and we compared the impact of the JCS approach to stroke prevention in AF, with the simple CHA 2 DS 2 -VASc based 2-step decision making strategy advocated by the ESC and NICE guidelines.
A C C E P T E D M A N U S C R I P T Results Table 1 shows the event rates for IS in Siu et al. 15 and Guo et al. 16 , and IS/TE in Komatsu et al. 11 and Lip et al. 14 per 100 person years based on CHA 2 DS 2 -VASc and CHADS 2 scores, which show broad comparability between these different populations for a given risk score value. Assuming that the Japanese AF population numbers 100,000, the estimated number of IS/TE events on no treatment was calculated by using the event rates of IS/TE based on Komatsu study (Table 2) .
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Whilst on warfarin, the risk reduction (RR) of overall event rates is 0. (Table 3 ).
In 
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We modeled these figures to potential stroke events among total AF population in Japan (n=889000) by using CHA 2 DS 2 -VASc score and CHADS 2 scores as follows: 4369 and 4817 for dabigatran 150mg bid, 6049 and 6448 for dabigatran 110mg bid, 5918 and 8056 for rivaroxaban (intention-to-treat; ITT), 5302 and 5731 for apixaban, 5843
and 8000 for edoxaban 60mg od (ITT), 7598 and 9454 for edoxaban 30mg od (ITT), respectively.
In every case, whether using warfarin or NOACs, prescribing OAC treatment based on the CHA 2 DS 2 -VASc score and the ESC/NICE management decision approach was modelled to have a numerically greater benefit for stroke prevention, as shown in Figure 2 .
Discussion
In this analysis, we present a modelling analysis showing that when consider antithrombotic treatment for Japanese AF patients, using a CHA 2 DS 2 -VASc-based approach advocated by the European and NICE guidelines would allow greater opportunities for stroke prevention (especially with the NOACs). Many international guidelines (eg ACCP, Canadian, etc) are still based the older CHADS 2 score, and our paper -whilst focused on the 2014 JCS guidelines -provides important learning points on missed opportunities for stroke prevention that would be generalizable to clinical practice outwith Japan.
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
In the 2014 JCS guidelines 7 , the CHADS 2 score is recommended to evaluate whether patients with nonvalvular AF 21 . Nonetheless, risk stratification based on CHADS 2 score itself might not be even widespread in clinical practice in Japan. Also, all clinical trials of NOACs were based on the CHADS 2 score. In the JCS guideline 7 , the non-CHADS 2 risk factors of 'Cardiomyopathy', 'Age of 65 to 74 years' and 'vascular disease' are defined as 'other risk factors'. These risk factors are essentially the 'A' and 'V' criteria of the CHA 2 DS 2 -VASc score, and cardiomyopathy is included within the 'C' criteria of CHA 2 DS 2 -VASc. However, OAC is only 'treatment to be considered' rather than being fully recommended.
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Therefore, this modeling analysis could provide us with more useful information on the optimal approach to stroke in Japanese AF patients. Indeed, CHA 2 DS 2 -VASc score may be more simpler for clinicians in stroke prevention for Japanese AF patients, and this score is already currently recommended in the other guidelines, ESC 5 , Asia Pacific Heart Rhythm Society (APHRS) guidelines 22 , American Heart Association/American College of Cardiology (AHA/ACC) 23 and National Institute for Health and Care Excellence (NICE) 6 .
What do current international guidelines say? Table 4 The 2014 NICE guidelines 6 have also shifted towards initially identifying truly low risk patients who will not benefit from antithrombotic therapy (that is CHA 2 DS 2 -VASc score=0 for men or score= 1 for females), as the first decision step. Subsequent to this step, oral anticoagulation can be offered to patients with ≥1 additional stroke risk factors, taking bleeding into account. In contrast to other expert-consensus guidelines, the NICE guidelines are based on systematic reviews, evidence appraisal and cost effectiveness, with a multidisciplinary guideline development group that includes patient representatives.
The CCS Guidelines 2014 24 recommends that OAC therapy be prescribed for most patients aged ≥ 65 years or However, a recent analysis 26 shows that the 'OAC not recommended' subgroup based on the 2014 CCS guideline, can still have a high 1 year stroke rate overall (>4%/year) if untreated, showing that such patients are not 'low risk'.
In the present modeling analysis using the 2014 JCS guideline as an illustrative example, we report the current situation of using the CHADS 2 score and highlight the missed opportunities for stroke prevention by using the CHADS 2 score instead of the CHA 2 DS 2 -VASc score.
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In the JCS guidelines, warfarin can be considered for stroke prevention in patients with CHADS 2 score=1, or 'CHADS 2 score =0 and other risk factors', because it is unclear whether the benefit of stroke prevention overweighs the risk of bleeding in such these patients. Also, when warfarin is administered, it is recommended that a target internationalized normalized ratio (INR) of 2.0 to 3.0 be set in patients <70 years, whilst patients age >70 years should be maintained with an INR 1.6 to 2.6, since some Japanese data suggest that an INR less than 1.6 increases the incidence of serious cerebral infarction and an INR above 2.6 increases serious bleeding complications. 27 28 An INR of 2.6-2.99 is also effective, but associated with a slightly increased risk in major haemorrhage. is the more important parameter 30 31 . Published studies from Asian population generally indicate a low TTR in these studies 32 33 34 35 .
When Asian and non-Asian patients receiving warfarin are compared, the risks of ischemic stroke, hemorrhagic stroke and major bleeding were twice higher in Asian than in non-Asian patients 36 . It is possible that a racial or genetic factor is involved in this difference, which has been pointed out for years, but we should also consider other factors because no such differences were observed in a comparison between Asian and non-Asian patients receiving dabigatran. In the Randomized Evaluation of Long-term Anticoagulation Therapy (RELY) substudy, the low average INR value and the low TTR in Asian patients may be the biggest reasons for the higher risks of ischemic stroke and hemorrhagic stroke. The sub-analysis of the RE-LY trial 1 revealed that the percentage of patients with a mean INR of 2 to 3 was 68.9% and 56.5% in non-Asian and Asian patients, respectively. In the . Indeed, guideline-adherent therapy is associated with much better outcomes in AF patients 37 38 .
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Limitations
Whilst Komatsu et al paper 11 does reflect an everyday clinical practice observational cohort setting, this does not hold true for the randomised trials, and therefore, modeling the expected benefit of NOACs on the basis of trial outcomes may not be the same as if derived from a clinical registry of these. All the NOACs are powerful anticoagulants, and would work well if used correctly, and when used in the appropriate patients. We have also made no assumptions on quality of anticoagulation control with warfarin (as measured by the time in therapeutic range), which may be fairly variable in the cohorts and related to prognosis 39 40 . Residual confounding may also be possible given the current comprehensive approach to stroke risk reduction in AF populations 41 . Second, although the numbers of patients were relatively small, the study period was long (mean 53 months), and the distribution of study patients showed broad comparability between these different populations for a given risk score value as described in Table 2 . Therefore, in the absence of better published data, we decided that the study
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by Komatsu et al. was reasonable enough to use for this modeling analysis. Moreover, according to a report from the J-RHYTHM registry, anticoagulant therapy is administered in more than 80% of patients with nonvalvular AF. 42 Therefore, it would be very difficult to find other contemporary data to model the natural incidence of ischemic stroke/systemic embolism in untreated Japanese patients with AF based on current clinical practice.
Third, the JCS guidelines recommends physician to prevent stroke by combination of CHADS 2 score and some consideration of 'other risk factors' (ie. cardiomyopathy, age 65-74 and vascular disease), and not soley on the CHADS 2 score per se. Therefore, stroke prophylaxis by using only CHADS 2 score, which is calculated in this modeling study, does not fully reflect the JCS guidelines. Fourth, female gender is not considered as independent risk factor for the incidence of stroke in Japanese NVAF patients, although the analysis was based in a largely anticoagulated registry cohort 43 . In contrast, female gender is an independent predictor for stroke in Chinese patients with nonvalvular AF and CHA 2 DS 2 -VASc score of ≤1 (HR: 2.3, 95% CI: 1.1-4.8) 44 . Moreover, Ogawa et al.
recommended use of CHA 2 DS 2 -VASc score in stroke prevention in the 2013 APHRS statement 22 . Hence, further research is needed to explore the influence of female gender on the incidence of stroke, amongst Japanese patients.
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Whilst the debate on whether using CHADS 2 score and other risk factors or simply using CHA 2 DS 2 -VASc score continues, both scoring systems have advantages and disadvantages 45 . However, we believe that the use of CHA 2 DS 2 -VASc score could make stroke prevention simple and consequently lead to the intial identification of "truly" low risk patients as a first step, following which effective stroke prevention can be offered to those with ≥1 In conclusion, our modelling analysis has shown that when considering antithrombotic treatment for Japanese AF patients, using a CHA 2 DS 2 -VASc-based approach would allow greater opportunities for stroke prevention.
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